Biologically Inspired Engineering, synbio, synthetic biology, crispr
Simons Chase 
There is a furious pace of innovation, deal flow and drug approvals for the new class of glucagon-like peptide 1 (GLP-1) receptor agonists and the emerging next gen Dual Agonists for the treatment of obesity and weight loss. Among mature pharmaceutics companies, the bandwagon took off when the sleepy backwater of GLP-1s for diabetes treatment … Read more
NeuroBo Pharmaceuticals is a clinical stage drug development company with a focus on weight loss and a GLP-1 Dual Agonist. Its most advanced drug candidate, A-1726, is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity. The IND approval is expected soon with Phase 1 trials commencing shortly thereafter. … Read more
Brad Loncar, Founder of BiotechTV, observed during an interview in October 2023 that some people were dressed as GLP-1 agonists for Halloween. He was interviewing Dr. Eric Topol, of Scripps Research Institute, who suggested they dress up as skeletons due to how little is known about the mode of action in this class of drugs … Read more
According to Persistence Market Research, the global bladder cancer treatment drugs market reached a size of $2bn in 2021 and is estimated to surge to $11.5bn by 2032, advancing at a 17% CAGR from 2022 to 2032. Two companies targeting high-risk non-muscle invasive bladder cancer (NMIBC) are nearing approval of drugs that show great promise. … Read more
Investment banking giant Goldman Sachs is making a major move into the life sciences sector with the launch of its first-ever dedicated fund, West Street Life Sciences I. The $650 million fund signals Goldman’s confidence in the burgeoning field and its potential for significant returns despite a recent period of setback and gloom – and … Read more
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. The company’s approach involves the direct injection into tumors of a unique product created from its DfuseRx℠ discovery platform. Valuation/risk: According to Stifel, Phase 3 valuations are up 33% since … Read more
The field of gene editing has taken a leap forward with the recent approvals of two CRISPR-based drugs, Casgevy and Lyfgenia, for the treatment of sickle cell disease (SCD). These groundbreaking therapies offer potential for treating this previously incurable disease, generating excitement and hope for patients and the science around gene editing. The Money Pricing: … Read more
There are 37 trillion or so cells in our bodies that work together to give us life. But it may surprise you that we still haven’t put a good number on how many distinct cell types there are within those trillions of cells. That’s why in 2016 a team of researchers from around the globe … Read more
Synthetic.com’s publisher and editor, Simons Chase, interviews Matthew McKnight. Matt is the Chief Commercial Officer of Ginkgo Bioworks where he also leads the company’s biosecurity platform, Concentric by Ginkgo. Prior to Ginkgo, Matt spent 7 years as an investor at IndUS Growth Partners and was the President and COO of Decision Resources Group. He has … Read more
BGI Group, a Chinese gene company, is collecting genetic data through prenatal tests from women in more than 50 countries for research on the traits of populations, raising concern that such a large DNA database could give China a technological advantage and the strategic edge to dominate global pharmaceuticals, according to a recent news report. … Read more